Moon Jae Chung

Dr. Moon Jae Chung

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
KLKyong Joo Lee
Kyong Joo Lee
SYSeung Woo Yi
Seung Woo Yi
MCMoon Jae Chung
Moon Jae Chung
SPSeung Woo Park
Seung Woo Park
SSSong si young Song
Song si young Song
JPJeong Youp Park
Jeong Youp Park
Lee KJ, et al. Yonsei Med J. 2013 May;54(3):643-649. https://doi.org/10.3349/ymj.2013.54.3.643

13 March 2012 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
CPChan Hyuk Park
Chan Hyuk Park
JCJoo Won Chung
Joo Won Chung
SJSeon Jung Jang
Seon Jung Jang
MCMoon Jae Chung
Moon Jae Chung
SBSeungmin Bang
Seungmin Bang
JPJeong Youp Park
Jeong Youp Park

12 December 2012 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
CPChan Hyuk Park
Chan Hyuk Park
MCMoon Jae Chung
Moon Jae Chung
TOTak Geun Oh
Tak Geun Oh
JPJeong Youp Park
Jeong Youp Park
SBSeungmin Bang
Seungmin Bang
SSSong si young Song
Song si young Song

12 June 2014 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
MCMoon Jae Chung
Moon Jae Chung
JPJeong Youp Park
Jeong Youp Park
SBSeungmin Bang
Seungmin Bang
SPSeung Woo Park
Seung Woo Park
SSSong si young Song
Song si young Song

14 December 2016 in Nutrition and Cancer
Verified
Journal Article
Closed access
SLSang Hoon Lee
Sang Hoon Lee
MCMoon Jae Chung
Moon Jae Chung
BKBun Kim
Bun Kim
HLHee Seung Lee
Hee Seung Lee
HLHyun Jik Lee
Hyun Jik Lee
JCJae Bock Chung
Jae Bock Chung
Nutritional status affects the prognosis of various tumors. The prognostic nutritional index (PNI) is the known predictor of postoperative outcome in resectable pancreatic cancer patients. This study aimed to validate the prognostic value of PNI in all stages of pancreatic cancer. We retrospectively reviewed 499 patients with pancreatic cancer who were diagnosed at Severance Hospital between January 2006 and December 2011. The PNI value was calculated as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm3) at initial diagnosis. The median patient age was 62 yr, and 289 were men. The study group comprised resectable disease (n = 121), locally advanced disease (n = 118), and metastatic disease (n = 260). Univariate and multivariate analysis revealed that PNI ≤ 49.5 at initial diagnosis, together with performance status, platelet count, and clinical stage, was significantly associated with overall survival (hazard ratio, 1.562; all P < 0.05). Patients with PNI ≤ 49.5 (n = 208) had shorter median overall survival compared to patients with high PNI (9.8 vs. 14.2 mo; log rank, P < 0.001). In clinical stage subgroup analysis, initial PNI ≤49.5 independently predicted shorter overall survival, especially in resectable and metastatic disease (P = 0.041, P = 0.002, respectively).